『The GLP-1 Podcast Show』のカバーアート

The GLP-1 Podcast Show

The GLP-1 Podcast Show

著者: Wisenetix
無料で聴く

今ならプレミアムプランが3カ月 月額99円

2026年5月12日まで。4か月目以降は月額1,500円で自動更新します。

概要

A whole new era of communication in GLP-1 is here!


Now you’ve got the sharpest minds in GLP-1 research right in your pocket. What’s best?

You can listen to them while driving to the hospital, walking between labs, traveling, or just running errands. It’s never been this good or this simple.


Welcome to The GLP-1 Podcast Show, a monthly podcast where you’ll hear cutting-edge perspectives and what’s working in the world of GLP-1. Our aspiration is to be the first place you are going to go to find out what's happening, the latest breakthroughs, clinical updates, and innovations in GLP-1 care and research.

All rights reserved.
衛生・健康的な生活 身体的病い・疾患
エピソード
  • Dr. Jason Itri: GLP-1 Microdosing Strategy | Ep. 08
    2026/05/04

    In this episode of The GLP-1 Podcast Show, I speak with Dr. Jason Itri, Founder of Longevity Health Clinic, about how GLP-1 therapies extend beyond weight loss into cardiometabolic optimization. We examine microdosing strategies, insulin resistance, inflammation pathways, and sustainable habit formation through precision prescribing. Dr. Itri highlights practical clinical applications for long-term metabolic health. Listen now on all major platforms!


    "Lower dose GLP-1 strategies can improve control over dietary habits by reducing impulsive food decisions and supporting consistent behavioral patterns over extended periods."


    Meet the guest: Dr. Jason Itri is a physician and the founder of Longevity Health Clinic in Virginia, specializing in cardiometabolic health, hormone optimization, and GLP-1 therapies. His work integrates biomarker testing with root-cause physiology to improve metabolic outcomes and reduce long-term disease risk. His clinical focus aligns with advancing precision approaches in obesity medicine and metabolic care.


    What you will learn:

    • (00:00) Highlight
    • (01:08) Introduction
    • (05:09) Microdosing strategy
    • (07:27) Habit control
    • (15:11) Risk markers
    • (17:11) Insulin resistance
    • (29:10) Muscle loss
    • (32:20) Final Questions


    𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

    Website: The GLP-1 Podcast Show

    Instagram: The GLP-1 Podcast Show

    LinkedIn: The GLP-1 Podcast Show

    続きを読む 一部表示
    33 分
  • Dr. Catherine Toomer: GLP-1 Dosing Strategy | Ep. 07
    2026/04/06

    In this episode of The GLP-1 Podcast Show, I speak with Dr. Catherine Toomer, founder of Total Weight Care Institute and a family medicine physician specializing in metabolic disease. The discussion examines long-term clinical experience using GLP-1 therapies, including dosing strategies, metabolic regulation, and patient-centered obesity care. She also explores insulin resistance, brain signaling, and emerging therapeutic applications. Listen now on all major platforms!


    “Appetite regulation is strongly influenced by brain signaling pathways, and correcting metabolic signaling often changes hunger perception and eating behavior without relying on willpower alone.”


    Meet the guest: Dr. Catherine Toomer is a family medicine physician and founder of Total Weight Care Institute, with more than fifteen years of clinical experience using GLP-1 therapies to address metabolic disease and obesity. Her work focuses on correcting metabolic dysregulation through evidence-based medical strategies and personalized care.


    What you will learn:

    • (00:00) Highlight
    • (00:31) Introduction
    • (01:52) Metabolic disease drivers
    • (05:33) Personalized dosing strategy
    • (07:17) Managing side effects
    • (19:44) Brain appetite signaling
    • (22:40) Future applications
    • (24:50) Final Questions


    𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

    Website: The GLP-1 Podcast Show

    Instagram: The GLP-1 Podcast Show

    LinkedIn: The GLP-1 Podcast Show

    続きを読む 一部表示
    29 分
  • Dr. Caroline Apovian: GLP-1 Game Changers | Ep. 06
    2026/03/02

    In this episode of The GLP-1 Podcast Show, I speak with Dr. Caroline Apovian, Professor of Medicine at Harvard Medical School and Co Director of the Center for Weight Management and Wellness at Brigham and Women’s Hospital, about the evolution of obesity treatment. We discuss why obesity is a chronic disease, how GLP-1 based therapies have changed clinical outcomes, and how they compare with lifestyle intervention and metabolic surgery. Dr. Apovian also addresses stigma, access barriers, and the risks of cosmetic use. Listen now on all major platforms!


    "Stigma surrounding obesity has forced clinicians to repeatedly prove that treating obesity also prevents cardiovascular disease and diabetes."


    Meet the guest: Dr. Caroline Apovian is Professor of Medicine at Harvard Medical School and Co Director of the Center for Weight Management and Wellness at Brigham and Women’s Hospital. A founding leader in obesity medicine, her research focuses on adipose tissue inflammation, cardiovascular risk, metabolic surgery, and pharmacotherapy for obesity.


    To hear Dr. Allison's actual remarks, view the recorded debate here!


    What you will learn:

    • (00:00) Highlight
    • (01:23) Introduction
    • (04:41) GLP-1 overview
    • (07:55) Obesity disease model
    • (13:35) Treatment comparisons
    • (19:59) Cardiovascular outcomes
    • (25:44) Cosmetic use debate
    • (33:22) Final Questions


    𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

    Website: The GLP-1 Podcast Show

    Instagram: The GLP-1 Podcast Show

    LinkedIn: The GLP-1 Podcast Show

    続きを読む 一部表示
    38 分
まだレビューはありません